Assenagon Asset Management S.A. Increases Stake in Charles River Laboratories International, Inc. $CRL

Assenagon Asset Management S.A. increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 104.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 65,879 shares of the medical research company’s stock after acquiring an additional 33,590 shares during the period. Assenagon Asset Management S.A. owned approximately 0.13% of Charles River Laboratories International worth $13,142,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of CRL. Jones Financial Companies Lllp lifted its stake in shares of Charles River Laboratories International by 167.6% during the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after purchasing an additional 1,074 shares in the last quarter. Empowered Funds LLC acquired a new stake in Charles River Laboratories International during the 1st quarter valued at $418,000. Creative Planning grew its holdings in Charles River Laboratories International by 7.1% during the 2nd quarter. Creative Planning now owns 8,894 shares of the medical research company’s stock valued at $1,349,000 after purchasing an additional 586 shares in the last quarter. Legal & General Group Plc increased its stake in Charles River Laboratories International by 12.3% during the 2nd quarter. Legal & General Group Plc now owns 106,201 shares of the medical research company’s stock worth $16,114,000 after buying an additional 11,614 shares during the period. Finally, Rhumbline Advisers increased its stake in Charles River Laboratories International by 9.7% during the 2nd quarter. Rhumbline Advisers now owns 95,142 shares of the medical research company’s stock worth $14,436,000 after buying an additional 8,412 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on CRL. Barclays lowered their price objective on Charles River Laboratories International from $215.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday, February 19th. JPMorgan Chase & Co. upped their target price on Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a research report on Monday, December 15th. UBS Group raised their price target on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. Bank of America upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $225.00 price target for the company in a research note on Monday, December 15th. Finally, Morgan Stanley set a $185.00 price target on shares of Charles River Laboratories International in a research report on Monday, December 1st. Ten analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $206.15.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $159.11 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.29 and a quick ratio of 1.02. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $228.88. The business’s 50-day moving average price is $179.61 and its two-hundred day moving average price is $180.53. The company has a market capitalization of $7.83 billion, a P/E ratio of -53.75, a price-to-earnings-growth ratio of 2.82 and a beta of 1.64.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. The company had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The business’s quarterly revenue was down .8% on a year-over-year basis. During the same period last year, the business earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. Analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.